App-Quantinova.ai

Use of Rituximab in the treatment of CTD-ILD in RA patients

Francesco Bini - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Rituximab

Bioelectrical impedance analysis (BIA and physical fitness in patients with idiopathic pulmonary fibrosis (IPF

Lorena Gallotti - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs

Francesco Bonella - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease

Taiki Furukawa - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis

Kakuhiro Yamaguchi - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Historical eye on idiopathic pulmonary fibrosis: redefining the mortality scenario

Sara Tomassetti - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Elevated apoptosis rate of alveolar lymphocytes (AL in idiopathic pulmonary fibrosis (IPF and nonspecific interstitial pneumonitis (NSIP – strong positive correlation with bronchoalvoelar lavage (BAL neutrophil count

Piotr Kopiński - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Decreased mitochondrial complex I activity in blood lymphocytes of patients with idiopathic pulmonary fibrosis

Emily Zifa - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Bronchoalveolar lavage differential cell count on assessment of patients with pulmonary fibrosis

Johanna Salonen - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation

Vincent Cottin - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Characterize Idiopathic Pulmonary Fibrosis using Respiratory Oscillometry

Joyce Wu - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg

Ekaterina Krauss - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Dynamics of diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis

Jesper Rømhild Davidsen - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: Real world experiencefrom a tertiary university hospital

Song Yee Kim - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Quantitative CT for the assessment of disease severity in interstitial lung disease

David G. Parr - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

The value of the surprise question to predict mortality in idiopathic pulmonary fibrosis

Nelleke Tak - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Prevalence and Characteristics of Patients with Idiopathic Pulmonary Fibrosis Admitted for Pneumonia Acquired in the Community

Irene Milagros Dominguez Zabaleta - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Cluster analysis and survival in patients with Idiopathic pulmonary fibrosis

Dimitrios Kalafatis - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF: analysis from the Swedish IPF registry

Jing Gao - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Prevalence of idiopathic pulmonary fibrosis in Japan and the US: a claims-based retrospective study

Yasuhiro Kondoh - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Filters

914 Abstracts